Skip to content
Calculator

Compound Explorer

All 696 entries in our encyclopedia in one table, filterable by evidence grade, FDA status, molecule class, half-life, route and WADA status. Every cell comes from the same dataset the entry pages are built from; open an entry for its sources. Grades follow our methodology, and the WADA column reads the 2026 Prohibited List as recorded in each entry. Nothing here is a recommendation, and nothing is sold or linked.

696 of 696 entries

CompoundClassCategoryFDA statusEvidenceHalf-lifeRouteWADA 2026
3PRGD2 Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
5-Amino-1MQSmall molecule, not a peptideMetabolicResearch ChemicalLowUndetermined in humansOralProhibited (S0 catch-all)
Abaloparatide Full entryPeptideHealing & RecoveryFDA ApprovedHigh≈ 1 hourInjectionNot on the 2026 List
Abarelix Full entryPeptideSexual HealthWithdrawnHigh≈ 10 daysInjectionUnsettled (S0 may apply)
ACE-031Protein, not a peptideResearchDiscontinuedMedium≈ 12.5 daysInjectionProhibited at all times (S4.3)
Acetyl Decapeptide-3PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Dipeptide-1 Cetyl EsterPeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Dipeptide-3 AminohexanoatePeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Heptapeptide-4PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Hexapeptide-1PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Hexapeptide-30PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Hexapeptide-37PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Hexapeptide-38PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Hexapeptide-49PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Hexapeptide-51 AmidePeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Octapeptide-3PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Pentapeptide-1PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl SH-Heptapeptide-1PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Tetrapeptide-11PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Tetrapeptide-15PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Tetrapeptide-2PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Tetrapeptide-22PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Tetrapeptide-3PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Tetrapeptide-5PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Tetrapeptide-9PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Acetyl Tripeptide-1PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
AclerastidePeptideHealing & RecoveryDiscontinuedLowLonger-acting than angiotensin-(1-7); applied topically once dailyTopical or eyeNot on the 2026 List
AdamaxPeptideCognitiveResearch ChemicalLowUndetermined in humansInjection, NasalProhibited (S0 catch-all)
AdipotidePeptideResearchPreclinicalLowPreclinical; not characterized in humansInjectionProhibited (S0 catch-all)
Adrenomedullin Full entryPeptideCardiovascularResearch ChemicalMediumAbout 22 minutes (circulating, in people)InjectionProhibited (S0 catch-all)
Adrenomedullin 2 Full entryPeptideCardiovascularResearch ChemicalLowNot characterised in peopleNot statedProhibited (S0 catch-all)
Adrenorphin (Metorphamide) Full entryPeptideCognitiveResearch ChemicalLowNot established for humans; a small endogenous peptide subject to rapid peptidase cleavageNot statedNot on the 2026 List
Adropin Full entryPeptideMetabolicResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Afamelanotide Full entryPeptideSexual HealthFDA ApprovedHigh≈ 15 hoursInjectionNot on the 2026 List
Agouti-Related Peptide (AgRP) Full entryPeptideMetabolicResearch ChemicalLowNot established for humans; an endogenous central signalling peptideNot statedNot on the 2026 List
AHK-CuPeptideCosmeticResearch ChemicalLowUndeterminedTopical or eyeProhibited (S0 catch-all)
Alamandine Full entryPeptideCardiovascularResearch ChemicalLowNot established for humans as a drug; a short endogenous RAS peptideNot statedNot on the 2026 List
Albiglutide Full entryProtein, not a peptideMetabolicDiscontinuedHigh≈ 5 daysInjectionProhibited (S0 catch-all)
Albuvirtide Full entryPeptideImmuneNot FDA ApprovedHighNot statedNot statedNot on the 2026 List
AlexamorelinPeptideGrowth HormoneResearch ChemicalLowNot measured in peopleInjectionProhibited at all times (S2.2.4)
AlF-NOTA-octreotide Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Alfatide II Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Alpha-MSH Full entryPeptideImmuneResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Alprostadil Full entrySmall molecule, not a peptideSexual HealthFDA ApprovedHighNo figure on the label, which reports that about 80% is metabolised in one pass through the lungsInjectionNot on the 2026 List
Amilomotide Full entryPeptide conjugateCognitiveNot FDA ApprovedMediumNot applicable: a vaccine; trials measured antibody titres, not the drugInjectionProhibited (S0 catch-all)
Amycretin Full entryPeptidePipeline & In-DevelopmentIn Clinical TrialsMediumSuitable for weekly SC / daily oralInjection, OralProhibited (S0 catch-all)
Amylin Full entryPeptideMetabolicResearch ChemicalLowNot reported for human amylin in the sources readNot statedProhibited (S0 catch-all)
Anamorelin Full entrySmall molecule, not a peptideGrowth HormoneNot FDA ApprovedHigh6 to 7 hours (terminal)OralProhibited at all times (S2.2.4)
Angiotensin II Full entryPeptideCardiovascularFDA ApprovedHigh≈ 1 minuteInjectionNot on the 2026 List
Angiotensin-(1-7) Full entryPeptideCardiovascularResearch ChemicalMediumNot stated in the sources readInjectionProhibited (S0 catch-all)
Anidulafungin Full entryPeptideImmuneFDA ApprovedHigh≈ 43 hoursNot statedNot on the 2026 List
ANP Full entryPeptideCardiovascularNot FDA ApprovedHighNot reported in the sources readNot statedUnsettled (S0 may apply)
Anserine Full entryPeptideLongevityDietary SupplementMediumShort after oral intake; partly hydrolysed by carnosinase enzymesOralNot on the 2026 List
AOD-9604 Full entryPeptideMetabolicResearch ChemicalMediumNot published for peopleInjectionProhibited at all times (S2.2.3)
Apamin Full entryPeptideCognitiveResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Apelin Full entryPeptideCardiovascularResearch ChemicalMediumNot reported in the abstracts readNot statedProhibited (S0 catch-all)
Apidaecin Full entryPeptideImmuneResearch ChemicalLowNot established for humans; a short linear peptide subject to proteolysis, analogs engineered for stabilityNot statedNot on the 2026 List
Apitegromab Full entryAntibody, not a peptidePipeline & In-DevelopmentFDA ApprovedHigh≈ 31.2 daysInjectionProhibited at all times (S4.3)
Apraglutide Full entryPeptidePipeline & In-DevelopmentIn DevelopmentHighNot reported in the sources readInjectionProhibited (S0 catch-all)
Aprotinin Full entryProtein, not a peptideCardiovascularDiscontinuedHigh≈ 150 minutesInjectionUnsettled (S0 may apply)
ARA-290 Full entryPeptideHealing & RecoveryIn Clinical TrialsMediumShort; no human value in the published abstractsInjectionProhibited at all times (S2.1.5)
Arenicin Full entryPeptideImmuneResearch ChemicalLowNot established for humans; a disulfide-stabilised beta-hairpin, more protease-resistant than linear AMPsNot statedNot on the 2026 List
Argireline Full entryPeptideCosmeticResearch ChemicalMediumNot reported in the sources read (topical use)Topical or eyeUnsettled (S0 may apply)
Asprosin Full entryPeptideMetabolicResearch ChemicalLowNot established for humans; an endogenous circulating hormoneNot statedNot on the 2026 List
Atosiban Full entryPeptideSexual HealthNot FDA ApprovedHigh≈ 1.7 hoursInjectionNot on the 2026 List
Augurin (ECRG4) Full entryPeptideImmuneResearch ChemicalLowNot established for humans as a drug; an endogenous secreted peptideNot statedNot on the 2026 List
Aurein Full entryPeptideImmuneResearch ChemicalLowNot established for humans; short cationic/amphipathic peptides subject to proteolysisNot statedNot on the 2026 List
AvexitidePeptideMetabolicIn Clinical TrialsMediumNot statedInjectionProhibited (S0 catch-all)
AvorelinPeptideSexual HealthDiscontinuedLowLong-acting; a single subcutaneous depot suppressed testosterone for about 40 weeksInjectionProhibited (S0 catch-all)
Azagly-nafarelinPeptideSexual HealthVeterinary OnlyLowNot reported in the sources readInjectionProhibited in males, at all times (S2.2.1)
AZD6234PeptidePipeline & In-DevelopmentIn Clinical TrialsLowNot reported in the sources readInjectionProhibited (S0 catch-all)
AzetirelinPeptideCognitiveDiscontinuedLowLonger-acting than TRH; no human pharmacokinetic value publishedNot statedProhibited (S0 catch-all)
B7-33PeptideCardiovascularPreclinicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Bacitracin Full entryBlend or mixtureImmuneFDA ApprovedHighNot applicable to the topical product; systemic use was abandoned for kidney toxicityTopical or eyeNot on the 2026 List
Balenine Full entryPeptideResearchResearch ChemicalMediumAbout 35 minutes in human plasma in vitro (2023)OralNot on the 2026 List
BalixafortidePeptideResearchIn Clinical TrialsMediumNot statedNot statedProhibited (S0 catch-all)
Beinaglutide Full entryPeptideMetabolicNot FDA ApprovedMediumShort; peak level 10 to 15 minutes after injectionInjectionUnsettled (S0 may apply)
Beta-Casomorphin-7 (BCM-7) Full entryPeptideMetabolicResearch ChemicalLowShort; degraded by the ectoenzyme CD10 (neprilysin), which limits its durationNot statedNot on the 2026 List
Beta-Endorphin Full entryPeptideCognitiveResearch ChemicalMediumNot reported in the sources readNot statedProhibited (S0 catch-all)
Beta-lipotropin Full entryProtein, not a peptideGrowth HormoneResearch ChemicalLow≈ 95 minutesNot statedNot on the 2026 List
Bimagrumab Full entryAntibody, not a peptidePipeline & In-DevelopmentIn Clinical TrialsMediumFc-mediated; weeksInjectionProhibited at all times (S4.3)
Bioactive Food Peptides Full entryPeptideResearchDietary SupplementMediumVariable — dipeptides and tripeptides absorbed intact via PepT1; larger peptides degradedOralNot on the 2026 List
Biotinoyl Tripeptide-1PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Bivalirudin Full entryPeptideCardiovascularFDA ApprovedHigh≈ 25 minutesInjectionNot on the 2026 List
Bleomycin Full entryPeptideResearchFDA ApprovedHigh≈ 2 hoursInjectionNot on the 2026 List
BNPPeptideCardiovascularDiagnostic Test OnlyHighAbout 18 minutes for recombinant BNP (nesiritide)Not statedNot on the 2026 List
Bofanglutide Full entryPeptidePipeline & In-DevelopmentIn Clinical TrialsMedium≈ 7 daysInjectionProhibited (S0 catch-all)
Bombesin Full entryPeptideMetabolicResearch ChemicalMediumShort-acting; given by continuous infusion in human research studiesInjectionNot on the 2026 List
Botulinum Toxin Full entryProtein, not a peptideCosmeticFDA ApprovedHighNot a blood half-life: it acts where it is injected, at nerve endingsInjectionNot on the 2026 List
BPC-157 Full entryPeptideHealing & RecoveryResearch ChemicalLowShort systemic half-life (minutes) but prolonged tissue effectInjection, OralProhibited at all times (S0)
Bradykinin Full entryPeptideCardiovascularResearch ChemicalMediumNot reported in the sources readNot statedProhibited (S0 catch-all)
Brevinin Full entryPeptideImmuneResearch ChemicalLowNot established for humans; cationic amphipathic peptides subject to proteolysisNot statedNot on the 2026 List
Brimapitide Full entryPeptideResearchNot FDA ApprovedMedium0.36-0.65 hours (geometric means) after a 60-minute intravenous infusion in healthy menNot statedProhibited (S0 catch-all)
BRN2 (POU3F2) Research PeptidePeptideCognitiveResearch ChemicalLowNot characterizedNot statedProhibited (S0 catch-all)
BronchogenPeptideLongevityResearch ChemicalLowNot reported in the sources readOralProhibited (S0 catch-all)
Buforin Full entryPeptideImmuneResearch ChemicalLowNot established for humans; a cationic peptide subject to proteolysisNot statedNot on the 2026 List
Bulevirtide Full entryPeptideImmuneFDA ApprovedHigh≈ 3 hoursInjectionNot on the 2026 List
Buserelin Full entryPeptideSexual HealthNot FDA ApprovedHighNot reported in the sources readInjection, NasalProhibited in males, at all times (S2.2.1)
C-peptide Full entryPeptideMetabolicResearch ChemicalMediumNot stated in the sources readInjectionProhibited (S0 catch-all)
Cagrilintide Full entryPeptideMetabolicIn Clinical TrialsMedium174-186 h (geometric means) after one dose of cagrilintide alone; 159-195 h when given weekly with semaglutideInjectionProhibited (S0 catch-all)
CagriSema Full entryBlend or mixturePipeline & In-DevelopmentIn DevelopmentHighCagrilintide 159-195 h; semaglutide 145-165 h (given together weekly, phase 1b)InjectionProhibited (S0 catch-all)
Calcitonin Full entryPeptideHealing & RecoveryFDA ApprovedHigh≈ 58 minutesInjection, NasalNot on the 2026 List
Canvuparatide Full entryPeptidePipeline & In-DevelopmentIn Clinical TrialsMedium79-95 h (prodrug) and 184-213 h (active peptide) after four weekly dosesInjectionProhibited (S0 catch-all)
Capreomycin Full entryPeptideImmuneDiscontinuedMediumNot statedNot statedUnsettled (S0 may apply)
Capromorelin Full entrySmall molecule, not a peptideGrowth HormoneVeterinary OnlyHighNot reported in people in the sources readNot statedProhibited at all times (S2.2.4)
Caprooyl Tetrapeptide-3PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Carbetocin Full entryPeptideSexual HealthNot FDA ApprovedHigh≈ 41 minutesNot statedNot on the 2026 List
CardiogenPeptideLongevityResearch ChemicalLowUndeterminedInjection, OralProhibited (S0 catch-all)
Carfilzomib Full entryPeptideResearchFDA ApprovedHigh≈ 1 hourInjectionNot on the 2026 List
Carnosine Full entryPeptideLongevityDietary SupplementMediumRapidly degraded in blood by serum carnosinaseOralNot on the 2026 List
Carperitide Full entryPeptideCardiovascularNot FDA ApprovedMedium≈ 3 minutesInjectionUnsettled (S0 may apply)
CART peptide Full entryPeptideMetabolicResearch ChemicalLowNot statedNot statedNot on the 2026 List
CartalaxPeptideLongevityResearch ChemicalLowUndeterminedOralProhibited (S0 catch-all)
Caspofungin Full entryPeptideImmuneFDA ApprovedHigh≈ 10 hoursInjectionNot on the 2026 List
Catestatin Full entryPeptideCardiovascularResearch ChemicalLowNot established for humans; an endogenous circulating peptideNot statedNot on the 2026 List
CathelicidinProtein, not a peptideImmuneResearch ChemicalLowNot measured in people in the sources readNot statedProhibited (S0 catch-all)
Cecropin Full entryPeptideImmuneResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
CenderitidePeptideCardiovascularIn Clinical TrialsLowNot stated in the sources readInjectionProhibited (S0 catch-all)
Cerebrolysin Full entryBlend or mixtureCognitiveNot FDA ApprovedHighVaries by componentInjectionUnsettled (S0 may apply)
CerlutenPeptideLongevityNot FDA ApprovedLowNot characterizedOralProhibited (S0 catch-all)
Certepetide Full entryPeptideResearchIn Clinical TrialsMedium≈ 2 hoursInjectionProhibited (S0 catch-all)
Ceruletide Full entryPeptideMetabolicDiscontinuedLowNot statedNot statedUnsettled (S0 may apply)
Cetrorelix Full entryPeptideSexual HealthFDA ApprovedHigh≈ 20.6 hoursInjectionNot on the 2026 List
CGRP Full entryPeptideCardiovascularResearch ChemicalMediumNot reported in the sources readNot statedProhibited (S0 catch-all)
Cholecystokinin Full entryPeptideMetabolicDiagnostic Test OnlyHighNot reported in the sources readNot statedUnsettled (S0 may apply)
ChonlutenPeptideLongevityResearch ChemicalLowUndeterminedOral, NasalProhibited (S0 catch-all)
Chromofungin Full entryPeptideCardiovascularResearch ChemicalLowNot established for humans as a drug; a chromogranin-A-derived peptideNot statedNot on the 2026 List
Cilengitide Full entryPeptideResearchIn Clinical TrialsMediumNot statedNot statedProhibited (S0 catch-all)
CJC-1293PeptideGrowth HormoneResearch ChemicalLowNot reported in the sources readNot statedProhibited at all times (S2.2.4)
CJC-1295 Full entryPeptideGrowth HormoneResearch ChemicalMedium5.8–8.1 days (with DAC)InjectionProhibited at all times (S2.2.4)
Clavanin Full entryPeptideImmuneResearch ChemicalLowNot established for humans; short peptide, chirality-inverted mimetics engineered for protease stabilityNot statedNot on the 2026 List
CNP Full entryPeptideCardiovascularResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Colistin Full entryPeptideImmuneFDA ApprovedHigh≈ 2.5 hoursInjectionNot on the 2026 List
Colivelin (CLN) Full entryPeptideCognitiveResearch ChemicalLowNot established for humans; a short synthetic peptide studied by CNS and nasal deliveryNot statedNot on the 2026 List
Collagen Peptides Full entryBlend or mixtureCosmeticDietary SupplementMediumNot establishedOralNot on the 2026 List
Colostrinin Full entryPeptideCognitiveDietary SupplementLowNot reported in the sources readOralNot on the 2026 List
ColulintidePeptidePipeline & In-DevelopmentDiscontinuedLowNot publishedInjectionProhibited (S0 catch-all)
Copeptin Full entryPeptideCardiovascularResearch ChemicalMediumAbout twice that of vasopressin (estimated initial half-life)Not statedNot on the 2026 List
Copper Cu 64 dotatate Full entryPeptide conjugateResearchFDA ApprovedHighNot statedNot statedNot on the 2026 List
Corifollitropin alfa Full entryProtein, not a peptideSexual HealthNot FDA ApprovedHigh≈ 65 hoursInjectionNot on the 2026 List
CortagenPeptideLongevityResearch ChemicalLowUndeterminedInjectionProhibited (S0 catch-all)
Cortexin Full entryBlend or mixtureCognitiveNot FDA ApprovedLowNot reported in the sources readInjectionUnsettled (S0 may apply)
Corticorelin Full entryPeptideGrowth HormoneFDA ApprovedHigh≈ 73 minutesInjectionProhibited at all times (S2.2.2)
Corticotropin Full entryPeptideGrowth HormoneFDA ApprovedHigh≈ 15 minutesInjectionProhibited at all times (S2.2.2)
Corticotropin-like intermediate peptide (CLIP) Full entryPeptideResearchResearch ChemicalLowNot stated in the sources readNot statedNot on the 2026 List
Cortistatin Full entryPeptideGrowth HormoneResearch ChemicalLowNot statedInjectionProhibited (S0 catch-all)
Cotadutide Full entryPeptidePipeline & In-DevelopmentDiscontinuedMedium≈ 11 hoursInjectionProhibited (S0 catch-all)
CP04Peptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Cyclic Glycine-Proline Full entryPeptideResearchResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Cyclo(His-Pro) Full entryPeptideResearchResearch ChemicalLowNot measured in people; long in mouse blood, with no figure givenInjectionProhibited (S0 catch-all)
Cyclosporine Full entryPeptideImmuneFDA ApprovedHigh≈ 8.4 hoursNot statedNot on the 2026 List
D-4F Full entryPeptideCardiovascularResearch ChemicalLowShort; peak 30 minutes to 2 hours after oral dosesOralProhibited (S0 catch-all)
Dactinomycin Full entryPeptideResearchFDA ApprovedHigh≈ 25 hoursInjectionNot on the 2026 List
DalazatidePeptideImmuneNot FDA ApprovedMediumNot reported in people; slow absorption, days of exposure in monkeysInjectionProhibited (S0 catch-all)
Dalbavancin Full entryPeptideImmuneFDA ApprovedHigh≈ 204 hoursInjectionNot on the 2026 List
Danegaptide Full entryPeptideCardiovascularIn Clinical TrialsMediumNot statedNot statedProhibited (S0 catch-all)
Danuglipron Full entrySmall molecule, not a peptidePipeline & In-DevelopmentDiscontinuedMediumNot reported; tested twice daily, then once dailyOralProhibited (S0 catch-all)
DapiglutidePeptideMetabolicIn Clinical TrialsMediumNot statedNot statedProhibited (S0 catch-all)
DAPTA Full entryPeptideImmuneNot FDA ApprovedMedium30-60 minutes (first phase) then 4-6 hours (second phase) after intravenous or intranasal dosingNasalProhibited (S0 catch-all)
Daptomycin Full entryPeptideImmuneFDA ApprovedHigh≈ 8 hoursInjectionNot on the 2026 List
Dasiglucagon Full entryPeptideMetabolicDiscontinuedHigh≈ 30 minutesInjectionNot on the 2026 List
DavalintidePeptideMetabolicDiscontinuedLowShort in blood (~26 min in rats) but a much longer action from slow receptor releaseNot statedNot on the 2026 List
Davunetide Full entryPeptideCognitiveIn Clinical TrialsMediumNot established in published human studiesNasalProhibited (S0 catch-all)
Dazdotuftide Full entryPeptide conjugateImmuneIn Clinical TrialsMediumNot reported in the sources readTopical or eyeProhibited (S0 catch-all)
Decapeptide-12PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Degarelix Full entryPeptideSexual HealthFDA ApprovedHigh≈ 53 daysInjectionNot on the 2026 List
Deltorphin Full entryPeptideCognitiveResearch ChemicalLowLonger-lived than ordinary peptides; the D-amino acid resists enzymatic breakdownNot statedNot on the 2026 List
Demoxytocin Full entryPeptideSexual HealthDiscontinuedMediumLonger-acting than oxytocin; buccal effect peaks in about 1-2 hoursOralNot on the 2026 List
Depreotide Full entryPeptideResearchDiscontinuedMediumNot reported in the sources readInjectionNot on the 2026 List
Dermcidin Full entryPeptideImmuneResearch ChemicalMediumHours on skin surfaceNot statedProhibited (S0 catch-all)
Dermorphin Full entryPeptideResearchResearch ChemicalLowLimited human PKNot statedNot on the 2026 List
Des-acyl Ghrelin (Unacylated Ghrelin) Full entryPeptideMetabolicResearch ChemicalMediumNot established as an approved drug; an endogenous circulating peptideNot statedNot on the 2026 List
Desirudin Full entryProtein, not a peptideCardiovascularDiscontinuedHigh≈ 2 hoursInjectionUnsettled (S0 may apply)
Deslorelin Full entryPeptideSexual HealthVeterinary OnlyMediumNot reported in the sources readInjectionProhibited in males, at all times (S2.2.1)
Desmopressin Full entryPeptideCardiovascularFDA ApprovedHigh≈ 2 hoursInjection, Oral, NasalProhibited at all times (S5)
Detirelix Full entryPeptideSexual HealthDiscontinuedMediumAt least 41 h in men after a single subcutaneous dose (by immunoassay)InjectionProhibited (S0 catch-all)
Difelikefalin Full entryPeptideHealing & RecoveryFDA ApprovedHigh≈ 27 hoursInjectionNot on the 2026 List
Dihexa Full entryPeptidomimeticCognitiveResearch ChemicalLowUndetermined in humansOralProhibited (S0 catch-all)
Dipeptide-2PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
DirucotidePeptideImmuneIn Clinical TrialsMediumNot statedNot statedProhibited (S0 catch-all)
Disomotide Full entryPeptideResearchNot FDA ApprovedMediumNot reported: a depot vaccine, measured by the T cells it raises rather than by blood levelsInjectionProhibited (S0 catch-all)
DolcanatidePeptideHealing & RecoveryNot FDA ApprovedLowNot stated in the sources readOralProhibited (S0 catch-all)
DOTA-EB-TATE Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
DOTA-LM3 Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
DOTA-MGS5Peptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
DOTAMTATEPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
DOTANOC Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Drosocin Full entryPeptideImmuneResearch ChemicalLowShort for the natural peptide; hydroxyproline-substituted analogs are several times more stable in serumNot statedNot on the 2026 List
DSIP Full entryPeptideCognitiveResearch ChemicalMediumNot measured in people; about 2 to 4 minutes after IV injection in dogs, a monkey and ratsInjectionProhibited (S0 catch-all)
Dulaglutide Full entryProtein, not a peptideMetabolicFDA ApprovedHigh≈ 5 daysInjectionNot on the 2026 List
DusquetidePeptideImmuneIn Clinical TrialsMediumNot statedNot statedProhibited (S0 catch-all)
Dynorphin Full entryPeptideCognitiveResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Ebiratide Full entryPeptideCognitiveDiscontinuedLowNot measured in peopleInjectionProhibited (S0 catch-all)
Ecallantide Full entryProtein, not a peptideImmuneFDA ApprovedHigh≈ 2 hoursNot statedNot on the 2026 List
ECC5004Small molecule, not a peptidePipeline & In-DevelopmentIn Clinical TrialsMediumNot reportedOralProhibited (S0 catch-all)
Ecnoglutide Full entryPeptideMetabolicNot FDA ApprovedHigh≈ 131 hoursInjectionUnsettled (S0 may apply)
Edotreotide Full entryPeptide conjugateResearchFDA ApprovedHighNot statedInjectionNot on the 2026 List
Edratide Full entryPeptideImmuneNot FDA ApprovedMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
EfinopegdutidePeptideMetabolicIn Clinical TrialsMediumNot statedNot statedProhibited (S0 catch-all)
Efmedaglutide alfaProtein, not a peptidePipeline & In-DevelopmentIn Clinical TrialsLowAbout 110 to 185 hoursInjectionProhibited (S0 catch-all)
EfocipegtrutidePeptide conjugatePipeline & In-DevelopmentIn Clinical TrialsLowAbout 72 to 191 hours in phase 1 (company abstracts)InjectionProhibited (S0 catch-all)
Efpeglenatide Full entryPeptide conjugatePipeline & In-DevelopmentIn Clinical TrialsHigh≈ 158 hoursInjectionProhibited (S0 catch-all)
Efruxifermin Full entryProtein, not a peptidePipeline & In-DevelopmentIn Clinical TrialsMedium3 to 3.5 days (PMID 33205064)InjectionUnsettled (S2.3 may apply)
Efsubaglutide alfa Full entryProtein, not a peptideMetabolicNot FDA ApprovedHighAbout 182–215 hours in type 2 diabetes (population model); mean 121 hours after single doses in healthy adultsInjectionUnsettled (S0 may apply)
Eftansomatropin alfaProtein, not a peptidePipeline & In-DevelopmentNot FDA ApprovedMediumNot stated in the sources readInjectionProhibited at all times (S2.2.3)
Elabela Full entryPeptideCardiovascularResearch ChemicalLowNot characterised in peopleNot statedProhibited (S0 catch-all)
Elagolix Full entrySmall molecule, not a peptideSexual HealthFDA ApprovedHigh≈ 6 hoursOralNot on the 2026 List
Elamipretide Full entryPeptideLongevityFDA ApprovedHighDosed once daily by subcutaneous injectionInjectionNot on the 2026 List
Elcatonin Full entryPeptideHealing & RecoveryNot FDA ApprovedMediumNot reported in the sources readInjectionNot on the 2026 List
Eloralintide Full entryPeptideMetabolicIn Clinical TrialsMediumSupports once-weekly dosingInjectionProhibited (S0 catch-all)
Elpamotide Full entryPeptideResearchNot FDA ApprovedMediumNot reported: a depot vaccine in oil adjuvant, judged by the T cells it raises rather than by blood levelsInjectionProhibited (S0 catch-all)
ElsiglutidePeptidePipeline & In-DevelopmentDiscontinuedLowNot reported in the sources readInjectionProhibited (S0 catch-all)
EM66 Full entryPeptideMetabolicResearch ChemicalLowNot established for humans as a drug; an endogenous granin peptideNot statedNot on the 2026 List
Emodepside Full entryPeptideResearchVeterinary OnlyMedium≈ 500 hoursOralProhibited (S0 catch-all)
EndolutenPeptideLongevityNot FDA ApprovedLowNot reportedOralProhibited (S0 catch-all)
Endomorphin-1 Full entryPeptideCognitiveResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Endomorphin-2 (EM-2) Full entryPeptideCognitiveResearch ChemicalLowVery short; the native peptide is rapidly degraded by peptidasesNot statedNot on the 2026 List
Endothelin-1 Full entryPeptideCardiovascularResearch ChemicalMediumAbout 1 to 2 minutes in plasma after infusion (initial phase); its constriction outlasts itNot statedProhibited (S0 catch-all)
Eneboparatide Full entryPeptidePipeline & In-DevelopmentIn Clinical TrialsMediumShort; peak 5-20 minutes after injectionInjectionProhibited (S0 catch-all)
Enfuvirtide Full entryPeptideImmuneDiscontinuedHigh≈ 3.8 hoursInjectionNot on the 2026 List
EnicepatidePeptidePipeline & In-DevelopmentIn Clinical TrialsMediumSupports once-weekly dosingInjectionProhibited (S0 catch-all)
Enkephalin Full entryPeptideCognitiveResearch ChemicalMediumNot reported in the sources readNot statedProhibited (S0 catch-all)
Enlicitide Full entryPeptideCardiovascularFDA ApprovedHigh≈ 14 hoursOralNot on the 2026 List
Enterostatin Full entryPeptideMetabolicResearch ChemicalLowNot characterised in peopleOralProhibited (S0 catch-all)
Epinecidin-1 Full entryPeptideImmuneResearch ChemicalLowNot established for humans; a short cationic peptide, variants engineered for stabilityNot statedNot on the 2026 List
Epithalamin Full entryBlend or mixtureLongevityResearch ChemicalLowNot reported in the sources readInjectionProhibited (S0 catch-all)
Epithalon Full entryPeptideLongevityResearch ChemicalLowNot characterised in humansInjectionProhibited (S0 catch-all)
Eptifibatide Full entryPeptideCardiovascularFDA ApprovedHigh≈ 2.5 hoursInjectionNot on the 2026 List
Equine Chorionic Gonadotropin Full entryProtein, not a peptideSexual HealthVeterinary OnlyLowLong (no figure in the abstracts read)InjectionProhibited in males, at all times (S2.2.1)
Erythropoietin (EPO) Full entryProtein, not a peptideCardiovascularFDA ApprovedHigh4 to 13 hours after IV epoetin alfa (kidney disease); peak 5 to 24 hours after SCInjectionProhibited at all times (S2.1.1)
Esculentin Full entryPeptideImmuneResearch ChemicalLowVery short for the native peptides; engineered long-acting constructs extend it greatlyNot statedNot on the 2026 List
Etelcalcetide Full entryPeptideMetabolicFDA ApprovedHigh≈ 3.5 daysInjectionNot on the 2026 List
Exenatide Full entryPeptideMetabolicFDA ApprovedHigh≈ 2.4 hoursInjectionNot on the 2026 List
FAP-2286 Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Feline Interferon OmegaProtein, not a peptideImmuneVeterinary OnlyLowNot reported in the sources readInjectionProhibited (S0 catch-all)
Felypressin Full entryPeptideCardiovascularNot FDA ApprovedMediumShort; local activityInjectionProhibited at all times (S5)
Fexapotide Full entryPeptideResearchIn Clinical TrialsMediumNot statedNot statedProhibited (S0 catch-all)
FGL PeptidePeptideCognitiveResearch ChemicalLowNot measured in peopleNot statedProhibited (S0 catch-all)
FK-13PeptideHealing & RecoveryResearch ChemicalMediumNot formally characterized in vivoNot statedProhibited (S0 catch-all)
Flotufolastat F 18 Full entryNot a peptideResearchFDA ApprovedHighNot reported in the sources readInjectionNot on the 2026 List
Fluciclatide Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Follistatin-315 Full entryProtein, not a peptideResearchPreclinicalLowShort; no figure in the sources readNot statedProhibited at all times (S4.3)
Follistatin-344Protein, not a peptideResearchPreclinicalLowProtein; tissue-boundInjectionProhibited at all times (S4.3)
Follitropin alfa Full entryProtein, not a peptideSexual HealthFDA ApprovedHigh≈ 42.6 hoursInjectionNot on the 2026 List
Follitropin beta Full entryProtein, not a peptideSexual HealthFDA ApprovedHigh≈ 33.4 hoursInjectionNot on the 2026 List
Follitropin delta Full entryProtein, not a peptideSexual HealthNot FDA ApprovedHigh≈ 55 hoursInjectionNot on the 2026 List
Forigerimod Full entryPeptideImmuneNot FDA ApprovedHighNot reported in the sources readInjectionProhibited (S0 catch-all)
FOXO4-DRIPeptideLongevityPreclinicalLowNot measured in peopleInjectionProhibited (S0 catch-all)
FPPRGD2 Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Galacto-RGD Full entryPeptideResearchIn Clinical TrialsMediumNot reported in the sources read; over 95% of circulating tracer was still intact at 120 minutesInjectionProhibited (S0 catch-all)
Galanin Full entryPeptideCognitiveResearch ChemicalMediumNot reported in the sources readNot statedProhibited (S0 catch-all)
Galanin-like Peptide (GALP) Full entryPeptideMetabolicResearch ChemicalLowNot established for humans as a drug; an endogenous signalling peptideNot statedNot on the 2026 List
Galinpepimut-SBlend or mixtureResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Gallium Ga 68 dotatate Full entryPeptide conjugateResearchFDA ApprovedHigh≈ 68 minutesNot statedNot on the 2026 List
Ganirelix Full entryPeptideSexual HealthFDA ApprovedHigh≈ 12.8 hoursInjectionNot on the 2026 List
Garetosmab Full entryAntibody, not a peptidePipeline & In-DevelopmentFDA ApprovedMediumFc-mediated; weeksInjectionProhibited at all times (S4.3)
Gastrin Full entryPeptideMetabolicResearch ChemicalLow≈ 6 minutesInjectionProhibited (S0 catch-all)
Gastrin-releasing peptide Full entryPeptideMetabolicResearch ChemicalMediumNot stated in the sources readInjectionProhibited (S0 catch-all)
GAWK (Chromogranin B 420-493) Full entryPeptideMetabolicResearch ChemicalLowNot established for humans as a drug; an endogenous granin peptideNot statedNot on the 2026 List
GDF11 Full entryProtein, not a peptideLongevityResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
GDF15 Full entryProtein, not a peptideLongevityIn Clinical TrialsHighNot reported in the sources readNot statedProhibited (S0 catch-all)
GHK-Cu Full entryPeptideHealing & RecoveryResearch ChemicalMediumUndetermined (systemic)Injection, Topical or eyeProhibited (S0 catch-all)
Ghrelin Full entryPeptideGrowth HormoneResearch ChemicalMediumNot reported in the sources readInjectionProhibited at all times (S2.2.4)
GHRP-1PeptideGrowth HormoneResearch ChemicalLowNot statedNot statedProhibited at all times (S2.2.4)
GHRP-2 Full entryPeptideGrowth HormoneNot FDA ApprovedMediumNot reported in humans in the abstracts we holdInjectionProhibited at all times (S2.2.4)
GHRP-4PeptideGrowth HormoneResearch ChemicalLowNot reported in the sources readNot statedProhibited at all times (S2.2.4)
GHRP-5PeptideGrowth HormoneResearch ChemicalLowNot reported in the sources readNot statedProhibited at all times (S2.2.4)
GHRP-6 Full entryPeptideGrowth HormoneResearch ChemicalMedium≈ 2.5 hoursInjectionProhibited at all times (S2.2.4)
GIP Full entryPeptideMetabolicResearch ChemicalMediumNot reported in the sources readNot statedProhibited (S0 catch-all)
Glatiramer Acetate Full entryNot a peptideImmuneFDA ApprovedHighNo blood half-life: the label reports that a substantial fraction of each dose is hydrolysed at the injection siteInjectionNot on the 2026 List
Glepaglutide Full entryPeptidePipeline & In-DevelopmentIn Clinical TrialsMediumSupports twice-weekly dosingInjectionProhibited (S0 catch-all)
Glicentin Full entryProtein, not a peptideMetabolicResearch ChemicalLowNot stated in the sources readNot statedProhibited (S0 catch-all)
GLP-1 Full entryPeptideMetabolicResearch ChemicalMedium≈ 2.3 minutesInjectionUnsettled (S0 may apply)
GLP-2 Full entryPeptideMetabolicResearch ChemicalMediumNot reported in the sources readNot statedProhibited (S0 catch-all)
Glucagon Full entryPeptideMetabolicFDA ApprovedHigh≈ 32 minutesInjection, NasalNot on the 2026 List
Glutathione Full entryPeptideLongevityResearch ChemicalLowNot reported in the sources readOralUnsettled (S0 may apply)
GlypromatePeptideCognitiveResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
GMA106Protein, not a peptidePipeline & In-DevelopmentIn Clinical TrialsLowNot publishedInjectionProhibited (S0 catch-all)
GnRF Analogue–Diphtheria Toxoid Conjugate Full entryPeptide conjugateSexual HealthVeterinary OnlyLowNot reported in the sources readInjectionProhibited (S0 catch-all)
Gomesin Full entryPeptideImmuneResearch ChemicalLowNot established for humans; natural gomesin is relatively short-lived in serum, while cyclic analogs are markedly more serum-stableNot statedNot on the 2026 List
Gonadorelin Full entryPeptideSexual HealthDiscontinuedMedium≈ 5 minutesInjectionProhibited in males, at all times (S2.2.1)
Gonadorelin (6-D-Phe)PeptideSexual HealthVeterinary OnlyLowNot reported in the sources readInjectionProhibited in males, at all times (S2.2.1)
Goralatide Full entryPeptideCardiovascularResearch ChemicalLowNot statedNot statedProhibited (S0 catch-all)
Goserelin Full entryPeptideSexual HealthFDA ApprovedHigh≈ 4.2 hoursInjectionProhibited in males, at all times (S2.2.1)
Gozetotide Full entryPeptidomimeticResearchFDA ApprovedHighNot statedInjectionNot on the 2026 List
Gramicidin Full entryPeptideImmuneFDA ApprovedHighTopical onlyTopical or eyeNot on the 2026 List
Growth hormone-releasing hormone Full entryPeptideGrowth HormoneResearch ChemicalMediumNot stated in the sources readInjectionProhibited at all times (S2.2.4)
Guanylin Full entryPeptideMetabolicResearch ChemicalLowNot stated in the sources readNot statedProhibited (S0 catch-all)
hBD-1 Full entryPeptideImmuneResearch ChemicalLowNot applicable — endogenous epithelial peptideNot statedProhibited (S0 catch-all)
hBD-2 Full entryPeptideImmuneResearch ChemicalLowNot applicable — endogenous epithelial peptideNot statedProhibited (S0 catch-all)
hBD-3 Full entryPeptideImmuneResearch ChemicalLowNot applicable — endogenous epithelial peptideNot statedProhibited (S0 catch-all)
HCG Full entryProtein, not a peptideGrowth HormoneFDA ApprovedHigh≈ 29 hoursInjectionProhibited in males, at all times (S2.2.1)
HD5 Full entryPeptideImmuneResearch ChemicalLowNot applicable — endogenous epithelial peptideNot statedProhibited (S0 catch-all)
HD6PeptideImmuneResearch ChemicalLowNot applicable: made and used locally in the intestinal cryptNot statedProhibited (S0 catch-all)
Hemopressin (Hp) Full entryPeptideMetabolicResearch ChemicalLowNot established for humans as a drug; a hemoglobin-derived peptideNot statedNot on the 2026 List
Hemorphin (Hemorphins) Full entryPeptideCognitiveResearch ChemicalLowShort; small endogenous peptides, with many stabilised analogs madeNot statedNot on the 2026 List
Hepcidin Full entryPeptideMetabolicResearch ChemicalMediumNot statedNot statedNot on the 2026 List
Hexanoyl Dipeptide-3 Norleucine AcetatePeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Hexapeptide-10PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Hexapeptide-11PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Hexapeptide-33PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Hexapeptide-9PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Hexarelin Full entryPeptideGrowth HormoneResearch ChemicalMediumNot measured in humansInjectionProhibited at all times (S2.2.4)
Histatin Full entryPeptideHealing & RecoveryResearch ChemicalMediumNot measured in people in the sources read; broken down by proteasesNot statedProhibited (S0 catch-all)
Histrelin Full entryPeptideSexual HealthFDA ApprovedHighNo half-life on the label: the implant keeps serum levels steady through the treatment periodInjectionProhibited in males, at all times (S2.2.1)
HM15136Peptide conjugatePipeline & In-DevelopmentIn Clinical TrialsLow≈ 89 hoursInjectionProhibited (S0 catch-all)
HM15275PeptidePipeline & In-DevelopmentIn Clinical TrialsLowAbout 110-132 hours (company poster)InjectionProhibited (S0 catch-all)
HNP-1 Full entryPeptideImmuneResearch ChemicalLowNot applicable — endogenous granule-stored peptideNot statedProhibited (S0 catch-all)
Homocarnosine Full entryPeptideCognitiveResearch ChemicalLowNot established for humans; a brain-compartment dipeptide handled within the GABA pathwayNot statedNot on the 2026 List
HRS-9531PeptidePipeline & In-DevelopmentIn Clinical TrialsMedium7-8 days (mean, after weekly doses)InjectionProhibited (S0 catch-all)
Humanin Full entryPeptideLongevityResearch ChemicalLowNot measured in the abstracts we holdInjectionProhibited (S0 catch-all)
Hyaluronic AcidNot a peptideCosmeticFDA ApprovedHighNo single figure: it depends on cross-linking and where it is injectedInjection, Topical or eyeNot on the 2026 List
HYNIC-TOC Full entryPeptide conjugateResearchNot FDA ApprovedMediumNot reported in the sources readInjectionUnsettled (S0 may apply)
Icatibant Full entryPeptideCardiovascularFDA ApprovedHighNot reported in the sources readInjectionNot on the 2026 List
Icotrokinra Full entryPeptideImmuneFDA ApprovedHigh≈ 12 hoursOralNot on the 2026 List
IGF-1 Full entryPeptideGrowth HormoneFDA ApprovedHigh≈ 5.8 hoursInjectionProhibited at all times (S2.3)
IGF-1 DES(1-3)PeptideResearchResearch ChemicalLowMinutes to low hoursInjectionProhibited at all times (S2.3)
IGF-1 LR3 Full entryProtein, not a peptideResearchResearch ChemicalLowNot measured in people; rats clear it faster than IGF-1InjectionProhibited at all times (S2.3)
Indium In 111 pentetreotide Full entryPeptide conjugateResearchFDA ApprovedHigh≈ 6 hoursNot statedNot on the 2026 List
Indolicidin Full entryPeptideImmuneResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
INSL3 Full entryProtein, not a peptideSexual HealthResearch ChemicalMediumNot statedNot statedNot on the 2026 List
INSL5 Full entryProtein, not a peptideMetabolicResearch ChemicalLowNot statedNot statedProhibited (S0 catch-all)
Insulin aspart Full entryProtein, not a peptideMetabolicFDA ApprovedHigh≈ 81 minutesInjectionProhibited at all times (S4.4.2)
Insulin degludec Full entryPeptideMetabolicFDA ApprovedHighThe label gives no half-life; after eight days of once-daily dosing in type 1 diabetes, peak concentration was reached at a median of 9 hoursInjectionProhibited at all times (S4.4.2)
Insulin degludec / liraglutide (IDegLira) Full entryPeptideMetabolicFDA ApprovedHigh≈ 25 hoursInjectionProhibited at all times (S4.4.2)
Insulin detemir Full entryPeptideMetabolicDiscontinuedHigh≈ 6 hoursInjectionProhibited at all times (S4.4.2)
Insulin efsitora alfa Full entryProtein, not a peptidePipeline & In-DevelopmentFDA ApprovedHigh≈ 408 hoursInjectionProhibited at all times (S4.4.2)
Insulin glargine Full entryPeptideMetabolicFDA ApprovedHighThe label gives no half-life; absorption is slower and more prolonged than NPH, with a relatively constant profile over 24 hours and no pronounced peakInjectionProhibited at all times (S4.4.2)
Insulin glargine / lixisenatide (iGlarLixi) Full entryPeptideMetabolicFDA ApprovedHigh≈ 3 hoursInjectionProhibited at all times (S4.4.2)
Insulin glulisine Full entryProtein, not a peptideMetabolicFDA ApprovedHigh≈ 42 minutesInjectionProhibited at all times (S4.4.2)
Insulin icodec Full entryProtein, not a peptideMetabolicFDA ApprovedHigh≈ 7 daysInjectionProhibited at all times (S4.4.2)
Insulin lispro Full entryProtein, not a peptideMetabolicFDA ApprovedHigh≈ 1 hourInjectionProhibited at all times (S4.4.2)
Insulin peglispro Full entryProtein, not a peptideMetabolicDiscontinuedHigh44.7 to 75.5 hours at steady state, about 2 to 3 days (PMID 24118909)InjectionProhibited at all times (S4.4.2)
Insulin tregopil Full entryProtein, not a peptideMetabolicIn Clinical TrialsLowUltra-fast onset, short actionOralProhibited at all times (S4.4.2)
Ipamorelin Full entryPeptideGrowth HormoneResearch ChemicalMedium≈ 2 hoursInjectionProhibited at all times (S2.2.4)
Irisin Full entryProtein, not a peptideMetabolicResearch ChemicalLowNot characterised in peopleNot statedProhibited (S0 catch-all)
Iseganan Full entryPeptideImmuneDiscontinuedHighNot applicable: not absorbed after oral rinsingOralProhibited (S0 catch-all)
Katacalcin Full entryPeptideResearchResearch ChemicalMediumNot stated in the sources readNot statedNot on the 2026 List
Kisspeptin-10 Full entryPeptideSexual HealthIn Clinical TrialsMediumShort; not established in the studies citedInjectionProhibited in males, at all times (S2.2.1)
Kisspeptin-54 Full entryPeptideSexual HealthIn Clinical TrialsMedium≈ 27.6 minutesInjectionProhibited in males, at all times (S2.2.1)
Klotho Peptide Full entryProtein, not a peptideLongevityResearch ChemicalMediumNot established in peopleNot statedProhibited (S0 catch-all)
KN056Protein, not a peptidePipeline & In-DevelopmentIn Clinical TrialsLow141-188 hours (single doses)InjectionProhibited (S0 catch-all)
KPV Full entryPeptideHealing & RecoveryResearch ChemicalLowNot measuredOralProhibited (S0 catch-all)
KR-12PeptideHealing & RecoveryResearch ChemicalMediumNot measuredNot statedProhibited (S0 catch-all)
Kyotorphin Full entryPeptideCognitiveResearch ChemicalLowBroken down rapidly in rodent brain and serum; no human figureNot statedProhibited (S0 catch-all)
LactoferricinPeptideImmuneResearch ChemicalMediumNot established in peopleNot statedProhibited (S0 catch-all)
Lancovutide Full entryPeptideResearchNot FDA ApprovedMediumAbout 5 days in bronchial epithelial cells and 25 to 91 days in lavage cells after one inhaled doseInhaledProhibited (S0 catch-all)
Lanreotide Full entryPeptideGrowth HormoneFDA ApprovedHigh≈ 26 daysInjectionNot on the 2026 List
Larazotide Full entryPeptideHealing & RecoveryIn Clinical TrialsMediumNot establishedOralProhibited (S0 catch-all)
LecirelinPeptideSexual HealthVeterinary OnlyLowNot reported in the sources readInjectionProhibited in males, at all times (S2.2.1)
LeconotidePeptideCognitiveNot FDA ApprovedLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Lepirudin Full entryProtein, not a peptideCardiovascularDiscontinuedHigh≈ 1.3 hoursInjectionUnsettled (S0 may apply)
LeuphasylPeptideCosmeticResearch ChemicalLowTopical onlyTopical or eyeUnsettled (S0 may apply)
Leuprolide Full entryPeptideSexual HealthFDA ApprovedHigh≈ 3 hoursInjectionProhibited in males, at all times (S2.2.1)
Linaclotide Full entryPeptideHealing & RecoveryFDA ApprovedHighNot systemically absorbed; acts luminallyOralNot on the 2026 List
Liraglutide Full entryPeptideMetabolicFDA ApprovedHigh≈ 13 hoursInjectionNot on the 2026 List
LivagenPeptideLongevityResearch ChemicalLowUndeterminedOralProhibited (S0 catch-all)
LivoletidePeptideMetabolicDiscontinuedLow2-3 hoursInjectionProhibited (S0 catch-all)
Lixisenatide Full entryPeptideMetabolicFDA ApprovedHigh≈ 3 hoursInjectionNot on the 2026 List
Lixivaptan Full entrySmall molecule, not a peptideCardiovascularDiscontinuedMediumNot reported in the sources readOralProhibited at all times (S5)
LL-37 Full entryPeptideHealing & RecoveryResearch ChemicalLowUndeterminedInjection, Topical or eyeProhibited (S0 catch-all)
Lonapegsomatropin Full entryProtein, not a peptideGrowth HormoneFDA ApprovedHigh≈ 30.7 hoursInjectionProhibited at all times (S2.2.3)
LSALT peptidePeptidePipeline & In-DevelopmentIn Clinical TrialsLow≈ 0.41 hoursInjectionProhibited (S0 catch-all)
Lucinactant Full entryBlend or mixtureResearchDiscontinuedHighNot studied in peopleNot statedUnsettled (S0 may apply)
Lunasin Full entryPeptideResearchResearch ChemicalLowNot reported in the sources readNot statedNot on the 2026 List
Lusupultide Full entryPeptideResearchNot FDA ApprovedMediumAbout 11 hours from rabbit lungs; 28 hours in miceNot statedProhibited (S0 catch-all)
Lutetium-177 DOTATATE Full entryPeptide conjugateResearchFDA ApprovedHigh≈ 71 hoursInjectionNot on the 2026 List
Lutropin alfa Full entryProtein, not a peptideSexual HealthDiscontinuedMedium10 to 12 hours (terminal)InjectionProhibited in males, at all times (S2.2.1)
Lypressin Full entryPeptideMetabolicDiscontinuedLowNot statedNot statedUnsettled (S0 may apply)
Macimorelin Full entryPeptidomimeticGrowth HormoneFDA ApprovedHigh≈ 4.1 hoursOralProhibited at all times (S2.2.4)
MagaininPeptideImmuneResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Manserin Full entryPeptideCognitiveResearch ChemicalLowNot established for humans as a drug; an endogenous granin peptideNot statedNot on the 2026 List
Maraciclatide Full entryPeptideResearchIn Clinical TrialsMedium≈ 1 hourInjectionProhibited (S0 catch-all)
Maridebart cafraglutidePeptide conjugatePipeline & In-DevelopmentIn Clinical TrialsMediumNot reported in the abstracts read; dosed every 4 or 8 weeks in phase 2InjectionProhibited (S0 catch-all)
Mastoparan Full entryPeptideImmuneResearch ChemicalLowNot established for humans; a membrane-active venom peptide used as a research toolNot statedNot on the 2026 List
Mazdutide Full entryPeptideMetabolicNot FDA ApprovedHighNot reported in the sources read; dosed once weeklyInjectionUnsettled (S0 may apply)
Mecasermin Full entryPeptideGrowth HormoneFDA ApprovedHighThe label gives no half-life; it reports bioavailability close to 100% after subcutaneous dosing in healthy subjects, and that over 80% of circulating IGF-1 is bound in a complex with IGFBP-3InjectionProhibited at all times (S2.3)
Mecasermin rinfabate Full entryProtein, not a peptideGrowth HormoneDiscontinuedMedium≈ 21 hoursInjectionProhibited at all times (S2.3)
Melanin-concentrating hormone Full entryPeptideMetabolicResearch ChemicalMediumNot stated in the sources readNot statedProhibited (S0 catch-all)
Melanocyte-stimulating hormone beta Full entryPeptideMetabolicResearch ChemicalMediumNot stated in the sources readNot statedProhibited (S0 catch-all)
Melanotan II Full entryPeptideSexual HealthResearch ChemicalMediumNot measured in humansInjectionProhibited (S0 catch-all)
Melatonin Full entrySmall molecule, not a peptideLongevityDietary SupplementMediumAbout 1 hour; 1.6 hours extended-releaseOral, Topical or eyeNot on the 2026 List
Melittin Full entryPeptideImmuneResearch ChemicalMediumNot reported in the sources readNot statedProhibited (S0 catch-all)
Melphalan Flufenamide Full entryPeptide conjugateResearchNot FDA ApprovedHigh≈ 2.1 minutesInjectionNot on the 2026 List
Menotropin Full entryProtein, not a peptideSexual HealthFDA ApprovedHigh≈ 12 hoursInjectionProhibited in males, at all times (S2.2.1)
Metreleptin Full entryProtein, not a peptideMetabolicFDA ApprovedHigh3.8 to 4.7 hoursInjectionNot on the 2026 List
MGFPeptideResearchResearch ChemicalLowShorter than systemic IGF-1's when unbound; not measured in peopleNot statedProhibited at all times (S2.3)
Micafungin Full entryPeptideImmuneFDA ApprovedHigh≈ 13.4 hoursNot statedNot on the 2026 List
Mifamurtide Full entryPeptide conjugateImmuneNot FDA ApprovedHighNot statedNot statedNot on the 2026 List
MK-677 Full entrySmall molecule, not a peptideGrowth HormoneResearch ChemicalMediumNot reported in the abstracts we holdOralProhibited at all times (S2.2.4)
Mod GRF 1-29PeptideGrowth HormoneResearch ChemicalLowNot measured in humansInjectionProhibited at all times (S2.2.4)
Modimelanotide Full entryPeptideImmuneDiscontinuedMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
MontirelinPeptideCognitiveDiscontinuedLowLonger-acting than TRH; no human pharmacokinetic value publishedNot statedProhibited (S0 catch-all)
Morphiceptin Full entryPeptideCognitiveResearch ChemicalLowShort; a small peptide degraded by brain and tissue peptidasesNot statedNot on the 2026 List
Motilin Full entryPeptideMetabolicResearch ChemicalLow≈ 4.6 minutesInjectionProhibited (S0 catch-all)
Motixafortide Full entryPeptideImmuneFDA ApprovedHigh≈ 2 hoursInjectionNot on the 2026 List
MOTS-c Full entryPeptideLongevityResearch ChemicalLowUndetermined in humansInjectionProhibited at all times (S4.4.1)
Murabutide Full entryPeptide conjugateImmuneNot FDA ApprovedLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Muramyl Dipeptide Full entryPeptide conjugateImmuneResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Murepavadin Full entryPeptidomimeticImmuneIn Clinical TrialsMedium2.5–5.3 hours (single intravenous doses, healthy men); 7.7 hours in a renal study's normal-function groupInjectionProhibited (S0 catch-all)
Myristoyl Hexapeptide-16PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Myristoyl Pentapeptide-17PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Myristoyl Tetrapeptide-12PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
NA-Selank AmidatePeptideCognitiveResearch ChemicalLowNot measuredNasalProhibited (S0 catch-all)
NAD+ Full entrySmall molecule, not a peptideLongevityResearch ChemicalMediumNot reported in the abstracts we holdInjectionUnsettled (S0 may apply)
Nafarelin Full entryPeptideSexual HealthFDA ApprovedHigh≈ 3 hoursNasalProhibited in males, at all times (S2.2.1)
Nangibotide Full entryPeptideImmuneIn Clinical TrialsMedium≈ 3 minutesInjectionProhibited (S0 catch-all)
Navepegritide Full entryPeptide conjugateGrowth HormoneFDA ApprovedHigh≈ 6.7 daysInjectionNot on the 2026 List
Nelipepimut-S Full entryPeptideResearchIn Clinical TrialsHighNot reported in the sources readNot statedProhibited (S0 catch-all)
Nemifitide Full entryPeptideCognitiveDiscontinuedMedium15–30 minutes (subcutaneous, most subjects)InjectionProhibited (S0 catch-all)
Nendratareotide UzatansinePeptide conjugateResearchNot FDA ApprovedLowNot reported in any journal paper; see the trial registry figures under Molecular DataInjectionProhibited (S0 catch-all)
NeoB Full entryPeptide conjugateResearchIn Clinical TrialsMedium≈ 27.3 minutesInjectionProhibited (S0 catch-all)
Nerinetide Full entryPeptideCognitiveIn Clinical TrialsMediumNot statedNot statedProhibited (S0 catch-all)
NERP-2 (Neuroendocrine Regulatory Peptide-2) Full entryPeptideMetabolicResearch ChemicalLowNot established for humans as a drug; endogenous VGF-derived peptidesNot statedNot on the 2026 List
Nesfatin-1 Full entryProtein, not a peptideMetabolicResearch ChemicalLowNot characterised in peopleNot statedProhibited (S0 catch-all)
Nesiritide Full entryPeptideCardiovascularDiscontinuedHighAbout 18 minutesInjectionUnsettled (S0 may apply)
Neurokinin A Full entryPeptideImmuneResearch ChemicalMediumNot stated in the sources readInjection, InhaledProhibited (S0 catch-all)
Neurokinin B Full entryPeptideSexual HealthResearch ChemicalMediumNot stated in the sources readInjectionProhibited (S0 catch-all)
Neuromedin B Full entryPeptideMetabolicResearch ChemicalLowNot established for humans; an endogenous, locally acting neuropeptideNot statedNot on the 2026 List
Neuromedin N (NN) Full entryPeptideCognitiveResearch ChemicalLowNot established for humans as a drug; an endogenous signalling peptide, rapidly degradedNot statedNot on the 2026 List
Neuromedin S Full entryPeptideCognitiveResearch ChemicalLowNot statedNot statedProhibited (S0 catch-all)
Neuromedin U Full entryPeptideMetabolicResearch ChemicalMediumNot characterised in peopleNot statedProhibited (S0 catch-all)
Neuropeptide AF (NPAF) Full entryPeptideMetabolicResearch ChemicalLowNot established for humans as a drug; an endogenous neuropeptideNot statedNot on the 2026 List
Neuropeptide B (NPB) Full entryPeptideMetabolicResearch ChemicalLowNot established for humans as a drug; an endogenous signalling peptideNot statedNot on the 2026 List
Neuropeptide EI (NEI) Full entryPeptideCognitiveResearch ChemicalLowNot established for humans as a drug; an endogenous neuropeptideNot statedNot on the 2026 List
Neuropeptide FF (NPFF) Full entryPeptideCognitiveResearch ChemicalLowNot established for humans as a drug; an endogenous signalling peptideNot statedNot on the 2026 List
Neuropeptide S Full entryPeptideCognitiveResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Neuropeptide W (NPW) Full entryPeptideMetabolicResearch ChemicalLowNot established for humans as a drug; an endogenous signalling peptideNot statedNot on the 2026 List
Neuropeptide Y Full entryPeptideCognitiveResearch ChemicalMediumNo figure in the sources read; the 2022 exercise study reports it is considerably shorter than immunoassays had establishedNot statedProhibited (S0 catch-all)
Neurotensin Full entryPeptideCognitiveResearch ChemicalMediumNot reported in the sources readNot statedProhibited (S0 catch-all)
NisinPeptideImmuneFood Additive OnlyHighNot reported in the sources read; it is eaten rather than injectedNot statedNot on the 2026 List
Nociceptin Full entryPeptideCognitiveResearch ChemicalLowNot reported in peopleNot statedProhibited (S0 catch-all)
Nocistatin (NST) Full entryPeptideCognitiveResearch ChemicalLowNot established for humans as a drug; an endogenous signalling peptideNot statedNot on the 2026 List
NODAGA-exendin-4 Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Nonapeptide-1PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Noopept Full entryPeptidomimeticCognitiveNot FDA ApprovedMediumNo figure in the abstracts read; eliminated more slowly in people than in rats or rabbitsOralUnsettled (S0 may apply)
NosiheptidePeptideImmuneResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
NPAS3 Research PeptidePeptideCognitiveResearch ChemicalLowNot reportedNot statedProhibited (S0 catch-all)
NPH insulin (isophane) Full entryProtein, not a peptideMetabolicFDA ApprovedHigh≈ 4.4 hoursInjectionProhibited at all times (S4.4.2)
Obestatin Full entryPeptideMetabolicResearch ChemicalLowNot characterised in peopleNot statedProhibited (S0 catch-all)
ObinepitidePeptidePipeline & In-DevelopmentIn Clinical TrialsLowNot publishedInjectionProhibited (S0 catch-all)
Octapeptide-2PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Octreotide Full entryPeptideGrowth HormoneFDA ApprovedHigh≈ 1.8 hoursInjectionNot on the 2026 List
OlatorepatidePeptidePipeline & In-DevelopmentIn Clinical TrialsMediumNot publishedInjectionProhibited (S0 catch-all)
Oligopeptide-68PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Omiganan Full entryPeptideHealing & RecoveryDiscontinuedHighNot established (topical gel only)Topical or eyeProhibited (S0 catch-all)
Oncocin Full entryPeptideImmuneResearch ChemicalLowNot established for humans; a short linear peptide, analogs engineered for protease stabilityNot statedNot on the 2026 List
Opiorphin Full entryPeptideCognitiveResearch ChemicalLowVery short; the natural peptide is rapidly degraded, motivating stabilized analogs (STR-324)Not statedNot on the 2026 List
Orexin-A Full entryPeptideCognitiveResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Orexin-BPeptideCognitiveResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Orforglipron Full entrySmall molecule, not a peptideMetabolicFDA ApprovedMedium≈ 39 hoursOralNot on the 2026 List
Oritavancin Full entryPeptideImmuneFDA ApprovedHigh≈ 245 hoursInjectionNot on the 2026 List
Ornipressin Full entryPeptideCardiovascularNot FDA ApprovedMediumNot stated in the sources readInjectionUnsettled (S0 may apply)
Osteocalcin Full entryPeptideHealing & RecoveryResearch ChemicalLowNot stated in the sources readNot statedProhibited (S0 catch-all)
Osteogenic growth peptidePeptideHealing & RecoveryResearch ChemicalLowNot characterised in peopleNot statedProhibited (S0 catch-all)
OvagenPeptideLongevityResearch ChemicalLowUndeterminedOralProhibited (S0 catch-all)
Oxyntomodulin Full entryPeptideMetabolicResearch ChemicalMedium≈ 12 minutesNot statedProhibited (S0 catch-all)
Oxytocin Full entryPeptideSexual HealthFDA ApprovedHigh≈ 3 minutesNasalNot on the 2026 List
OzarelixPeptideSexual HealthNot FDA ApprovedLowNot reported in the sources readNot statedProhibited (S0 catch-all)
P21PeptidomimeticCognitiveResearch ChemicalLowNot established in human studiesNot statedProhibited (S0 catch-all)
PACAP Full entryPeptideCognitiveResearch ChemicalMediumNot statedNot statedProhibited (S0 catch-all)
Pal-GHKPeptideCosmeticResearch ChemicalMediumTopical onlyTopical or eyeUnsettled (S0 may apply)
Palmitoyl Dipeptide-10PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Palmitoyl Dipeptide-5 Diaminobutyroyl HydroxythreoninePeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Palmitoyl Dipeptide-5 DiaminohydroxybutyratePeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Palmitoyl Dipeptide-7PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Palmitoyl Hexapeptide-12PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Palmitoyl Hexapeptide-14PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Palmitoyl Pentapeptide-4PeptideCosmeticResearch ChemicalMediumTopical only; not a systemic drugTopical or eyeUnsettled (S0 may apply)
Palmitoyl Tetrapeptide-10PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Palmitoyl Tetrapeptide-20PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Palmitoyl Tetrapeptide-7PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Palmitoyl Tripeptide-28PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Palmitoyl Tripeptide-38PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Palmitoyl Tripeptide-5PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Palmitoyl Tripeptide-8PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Palopegteriparatide Full entryPeptide conjugateHealing & RecoveryFDA ApprovedHigh≈ 60 hoursInjectionNot on the 2026 List
PAMP (Proadrenomedullin N-terminal 20 Peptide) Full entryPeptideCardiovascularResearch ChemicalLowNot established for humans as a drug; an endogenous precursor peptideNot statedNot on the 2026 List
PancragenPeptideMetabolicResearch ChemicalLowNot statedNot statedProhibited (S0 catch-all)
Pancreastatin Full entryPeptideMetabolicResearch ChemicalMediumNot established for humans as a drug; an endogenous circulating peptideInjectionNot on the 2026 List
Pancreatic polypeptide Full entryPeptideMetabolicResearch ChemicalMedium≈ 6.9 minutesInjectionProhibited (S0 catch-all)
Parathyroid hormone (1-84) Full entryProtein, not a peptideHealing & RecoveryDiscontinuedHigh≈ 3 hoursInjectionUnsettled (S0 may apply)
Parathyroid hormone-related protein Full entryProtein, not a peptideHealing & RecoveryResearch ChemicalMediumNot stated in the sources readInjectionProhibited (S0 catch-all)
Pasireotide Full entryPeptideGrowth HormoneFDA ApprovedHighNot reported in the sources readInjectionNot on the 2026 List
PB-718PeptidePipeline & In-DevelopmentIn Clinical TrialsLowNot reported in the sources readInjectionProhibited (S0 catch-all)
PE-22-28PeptideCognitiveResearch ChemicalLowUndetermined in humansNot statedProhibited (S0 catch-all)
Peforelin Full entryPeptideSexual HealthVeterinary OnlyLowNot reported in the sources readInjectionProhibited in males, at all times (S2.2.1)
PEG-MGFPeptideResearchResearch ChemicalLowNot measured: no pharmacokinetic study of PEG-MGF existsNot statedProhibited at all times (S2.3)
Pegbelfermin Full entryProtein, not a peptidePipeline & In-DevelopmentDiscontinuedMediumWeekly dosingInjectionUnsettled (S2.3 may apply)
Pegbovigrastim Full entryProtein, not a peptideImmuneVeterinary OnlyLowNot reported in the sources readInjectionProhibited (S0 catch-all)
Pegcetacoplan Full entryPeptide conjugateImmuneFDA ApprovedHigh≈ 8.6 daysInjectionNot on the 2026 List
Peginesatide Full entryPeptideCardiovascularDiscontinuedHigh≈ 47.9 hoursInjectionProhibited at all times (S2.1.1)
Pegmolesatide Full entryPeptide conjugateCardiovascularNot FDA ApprovedMediumLong (dosed every four weeks); no figure in the sources readInjectionProhibited at all times (S2.1.1)
PegozaferminProtein, not a peptidePipeline & In-DevelopmentIn Clinical TrialsMedium55 to 100 hours (PMID 37562970)InjectionUnsettled (S2.3 may apply)
Pegsebrenatide Full entryPeptide conjugateCognitiveIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Pegvisomant Full entryProtein, not a peptideGrowth HormoneFDA ApprovedHigh60 to 138 hours (mean estimates after single or multiple doses)InjectionUnsettled (S2.2.3 may apply)
PemvidutidePeptidePipeline & In-DevelopmentIn Clinical TrialsMediumNot reported; dosed once weekly in trialsInjectionProhibited (S0 catch-all)
Pentagastrin Full entryPeptideMetabolicDiscontinuedMediumNot statedNot statedUnsettled (S0 may apply)
Pentapeptide-3PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Pentapeptide-31PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Pentigetide (IgE Pentapeptide) Full entryPeptideImmuneResearch ChemicalMediumNot established; a short synthetic pentapeptide given topically in trialsNasal, Topical or eyeNot on the 2026 List
Pentixafor Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Pentixather Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
PEPITEMPeptideImmunePreclinicalLowNot statedNot statedProhibited (S0 catch-all)
Peptide YY Full entryPeptideMetabolicResearch ChemicalMediumNot reported in the sources readNot statedProhibited (S0 catch-all)
PetrelintidePeptidePipeline & In-DevelopmentIn Clinical TrialsMediumEngineered for once-weekly dosingInjectionProhibited (S0 catch-all)
Pexiganan Full entryPeptideHealing & RecoveryDiscontinuedHighTopical; minimal systemic absorptionTopical or eyeProhibited (S0 catch-all)
PHM-27 Full entryPeptideMetabolicResearch ChemicalLowNot statedInjectionProhibited (S0 catch-all)
Phoenixin Full entryPeptideSexual HealthResearch ChemicalLowNot established for humans; an endogenous signalling peptideNot statedNot on the 2026 List
Piflufolastat F 18 Full entrySmall molecule, not a peptideResearchFDA ApprovedHigh≈ 3.47 hoursInjectionNot on the 2026 List
PinealonPeptideLongevityResearch ChemicalLowUndeterminedOralProhibited (S0 catch-all)
Piscidin Full entryPeptideImmuneResearch ChemicalLowNot established for humans; short cationic peptides, variable stabilityNot statedNot on the 2026 List
Plantaricin Full entryPeptideImmuneResearch ChemicalLowNot established for humans; small heat-stable bacteriocins, stable across pH and heat in food systemsNot statedNot on the 2026 List
Plecanatide Full entryPeptideHealing & RecoveryFDA ApprovedHighNot systemically absorbed; acts luminallyOralNot on the 2026 List
PlectasinPeptideImmunePreclinicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Pleurocidin Full entryPeptideImmuneResearch ChemicalLowShort and delivery-limited in the body; stereochemistry and formulation strongly affect exposureNot statedNot on the 2026 List
Plitidepsin Full entryPeptideResearchNot FDA ApprovedMedium21 to 44 hours in plasmaInjectionNot on the 2026 List
PNC-27PeptideResearchPreclinicalLowNot establishedNot statedProhibited (S0 catch-all)
Polaprezinc Full entryPeptide conjugateHealing & RecoveryNot FDA ApprovedHighNot stated in the sources readOralNot on the 2026 List
Polyethylene glycol loxenatide Full entryPeptide conjugateMetabolicNot FDA ApprovedHigh≈ 121 hoursInjectionUnsettled (S0 may apply)
Polymyxin B Full entryPeptideImmuneFDA ApprovedHigh≈ 4.1 hoursInjectionNot on the 2026 List
Ponericin Full entryPeptideImmuneResearch ChemicalLowNot established for humans; a short linear peptide, engineered analogs improve stabilityNot statedNot on the 2026 List
Porcine FSH Full entryProtein, not a peptideSexual HealthVeterinary OnlyLowNot reported in the sources readInjectionProhibited (S0 catch-all)
Porcine Insulin Zinc Suspension Full entryProtein, not a peptideMetabolicVeterinary OnlyMediumNot reported in the sources readInjectionProhibited at all times (S4.4.2)
Posatirelin Full entryPeptideCognitiveDiscontinuedMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Pramlintide Full entryPeptideMetabolicDiscontinuedHigh≈ 48 minutesInjectionUnsettled (S0 may apply)
Preptin Full entryPeptideMetabolicResearch ChemicalLowNot characterised in peopleNot statedProhibited (S0 catch-all)
Prokineticin 1 (EG-VEGF) Full entryPeptideSexual HealthResearch ChemicalLowNot established for humans as a drug; an endogenous circulating peptideNot statedNot on the 2026 List
Prokineticin 2 Full entryPeptideCognitiveResearch ChemicalLowNot established for humans; an endogenous signalling peptideNot statedNot on the 2026 List
Prolactin-releasing peptide Full entryPeptideMetabolicResearch ChemicalLowNot stated in the sources readNot statedNot on the 2026 List
Prolyl-Hydroxyproline Full entryPeptideResearchResearch ChemicalLowNot reported in the sources readNot statedNot on the 2026 List
ProstamaxPeptideLongevityNot FDA ApprovedLowNot characterized in humansOralProhibited (S0 catch-all)
Prostatilen Full entryBlend or mixtureLongevityNot FDA ApprovedLowNot reported in the sources readInjectionUnsettled (S0 may apply)
Protegrin Full entryPeptideImmuneResearch ChemicalLowNot established for humans; a disulfide-stabilised beta-hairpin, more protease-resistant than linear AMPsNot statedNot on the 2026 List
Protirelin Full entryPeptideGrowth HormoneDiscontinuedHighNot reported in the abstracts readInjectionProhibited (S0 catch-all)
PSMA I&S Full entryNot a peptideResearchIn Clinical TrialsMedium≈ 4.15 hoursInjectionProhibited (S0 catch-all)
PSMA-1007 Full entryNot a peptideResearchNot FDA ApprovedMediumNot reported in the sources readInjectionUnsettled (S0 may apply)
PT-141 Full entryPeptideSexual HealthFDA ApprovedHigh≈ 2.7 hoursInjectionNot on the 2026 List
QRFP (26RFa) Full entryPeptideMetabolicResearch ChemicalLowNot established for humans; an endogenous, centrally acting neuropeptideNot statedNot on the 2026 List
Ramoplanin Full entryPeptideImmuneDiscontinuedMediumNot reported in the sources readOralProhibited (S0 catch-all)
Recombinant Human Endostatin Full entryProtein, not a peptideResearchNot FDA ApprovedMediumNot reported in the sources readInjectionUnsettled (S0 may apply)
Regular human insulin Full entryProtein, not a peptideMetabolicFDA ApprovedHigh≈ 1.5 hoursInjectionProhibited at all times (S4.4.2)
Relamorelin Full entryPeptidePipeline & In-DevelopmentIn Clinical TrialsMediumNot reported in the abstracts readInjectionProhibited at all times (S2.2.4)
Relaxin-3 Full entryProtein, not a peptideCognitiveResearch ChemicalLowNot statedNot statedProhibited (S0 catch-all)
Relugolix Full entrySmall molecule, not a peptideSexual HealthFDA ApprovedHigh≈ 61 hoursOralNot on the 2026 List
Retatrutide Full entryPeptideMetabolicIn Clinical TrialsMedium≈ 6 daysInjectionProhibited (S0 catch-all)
Retinalamin Full entryBlend or mixtureLongevityNot FDA ApprovedLowNot reported in the sources readInjectionUnsettled (S0 may apply)
Rezafungin Full entryPeptideImmuneFDA ApprovedHigh≈ 152 hoursInjectionNot on the 2026 List
RFRP-3 (GnIH) Full entryPeptideSexual HealthResearch ChemicalLowNot established for humans as a drug; an endogenous signalling peptideNot statedNot on the 2026 List
RM2 Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Romidepsin Full entryPeptideResearchFDA ApprovedHigh≈ 3 hoursInjectionNot on the 2026 List
Romiplostim Full entryProtein, not a peptideImmuneFDA ApprovedHighNot reported in the sources readInjectionNot on the 2026 List
Romurtide Full entryPeptide conjugateImmuneNot FDA ApprovedMedium≈ 2.7 hoursInjectionUnsettled (S0 may apply)
Rotigaptide Full entryPeptideCardiovascularDiscontinuedMediumNot statedNot statedProhibited (S0 catch-all)
RovatirelinPeptidomimeticCognitiveIn Clinical TrialsMediumNot statedNot statedProhibited (S0 catch-all)
Rubiscolin Full entryPeptideCognitiveResearch ChemicalLowNot established for humans; a small food-derived peptide, unusually active after oral dosing in miceNot statedNot on the 2026 List
Rusalatide Full entryPeptideHealing & RecoveryNot FDA ApprovedLowShort; no figure in the abstracts read (a 30 kDa PEG derivative lasted about 19 times longer in mice)Topical or eyeProhibited (S0 catch-all)
Rusfertide Full entryPeptideMetabolicFDA ApprovedHigh≈ 28.6 hoursInjectionNot on the 2026 List
Ruxotemitide Full entryPeptideResearchIn Clinical TrialsLow160 minutes in human plasma in a test tube; no in-body half-life in the abstracts readOralProhibited (S0 catch-all)
Salusin-alpha Full entryPeptideCardiovascularResearch ChemicalLowNot stated in the sources readNot statedNot on the 2026 List
Salusin-beta Full entryPeptideCardiovascularResearch ChemicalLowNot stated in the sources readNot statedNot on the 2026 List
SAR-bisPSMAPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
SARTATEPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Satoreotide Tetraxetan Full entryPeptide conjugateResearchIn Clinical TrialsMedium≈ 127 hoursInjectionProhibited (S0 catch-all)
Satoreotide Trizoxetan Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Secretin Full entryPeptideMetabolicFDA ApprovedHigh≈ 45 minutesInjectionNot on the 2026 List
Secretoneurin (SN) Full entryPeptideCardiovascularResearch ChemicalLowNot established for humans as a drug; an endogenous circulating peptideNot statedNot on the 2026 List
Seglitide Full entryPeptidePipeline & In-DevelopmentDiscontinuedMediumAbout 45 minutes in people (vs ~2 minutes for somatostatin)InjectionProhibited (S0 catch-all)
Selank Full entryPeptideCognitiveNot FDA ApprovedMediumNot measured in humansNasalUnsettled (S0 may apply)
SelepressinPeptideCardiovascularDiscontinuedMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Semaglutide Full entryPeptideMetabolicFDA ApprovedHigh≈ 7 daysInjection, OralNot on the 2026 List
Semax Full entryPeptideCognitiveNot FDA ApprovedMediumNot measured in humansNasalUnsettled (S0 may apply)
Serelaxin Full entryProtein, not a peptideCardiovascularDiscontinuedHighMean terminal half-life about 7 to 8 hours after a 24-hour infusion (PMID 25511105)InjectionProhibited (S0 catch-all)
Sermorelin Full entryPeptideGrowth HormoneDiscontinuedMediumNot established in our sourcesInjectionProhibited at all times (S2.2.4)
Serpinin Full entryPeptideCardiovascularResearch ChemicalLowNot established for humans as a drug; an endogenous signalling peptideNot statedNot on the 2026 List
Setmelanotide Full entryPeptideMetabolicFDA ApprovedHigh≈ 11 hoursInjectionNot on the 2026 List
SHLP2PeptideLongevityResearch ChemicalMediumNot formally characterized in humansNot statedProhibited (S0 catch-all)
SHLP6PeptideLongevityResearch ChemicalLowNot formally characterizedNot statedProhibited (S0 catch-all)
Sialorphin Full entryPeptideCognitiveResearch ChemicalLowShort; a small peptide, with lipidated analogs made to improve stabilityNot statedNot on the 2026 List
SiTATE Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Snakin Full entryPeptideImmuneResearch ChemicalLowNot established for humans; disulfide-stabilised and notably heat-stableNot statedNot on the 2026 List
Solnatide Full entryPeptidePipeline & In-DevelopmentIn Clinical TrialsMediumNot reported in the sources readInhaledProhibited (S0 catch-all)
Somapacitan Full entryProtein, not a peptideGrowth HormoneFDA ApprovedHigh≈ 60 hoursInjectionProhibited at all times (S2.2.3)
Somatostatin Full entryPeptideGrowth HormoneNot FDA ApprovedHighA few minutes in plasma, which is why it is given by continuous infusionNot statedNot on the 2026 List
Somatrem Full entryProtein, not a peptideGrowth HormoneDiscontinuedMedium≈ 3 hoursInjectionProhibited at all times (S2.2.3)
Somatrogon Full entryProtein, not a peptideGrowth HormoneFDA ApprovedHigh≈ 37.7 hoursInjectionProhibited at all times (S2.2.3)
Somatropin (HGH) Full entryProtein, not a peptideGrowth HormoneFDA ApprovedHigh≈ 3.5 hoursInjectionProhibited at all times (S2.2.3)
Sometribove Full entryProtein, not a peptideGrowth HormoneVeterinary OnlyLowNot reported in the sources readInjectionProhibited at all times (S2.2.3)
SonefpeglutidePeptidePipeline & In-DevelopmentIn Clinical TrialsLowNot reported in peopleInjectionProhibited (S0 catch-all)
Sotatercept Full entryProtein, not a peptideCardiovascularFDA ApprovedHigh≈ 24 daysInjectionProhibited at all times (S2.1.4)
Sovateltide Full entryPeptideCognitiveNot FDA ApprovedMediumNot statedNot statedNot on the 2026 List
Spexin Full entryPeptideMetabolicResearch ChemicalLowNot characterised in peopleNot statedProhibited (S0 catch-all)
Spinorphin Full entryPeptideCognitiveResearch ChemicalLowNot established for humans; a small endogenous peptideNot statedNot on the 2026 List
SS-31 (Elamipretide) Full entryPeptideLongevityFDA ApprovedHighNot stated on the FORZINITY labelInjectionNot on the 2026 List
Substance P Full entryPeptideImmuneResearch ChemicalMediumNot measured in people in the sources readNot statedProhibited (S0 catch-all)
Surotomycin Full entryPeptideImmuneDiscontinuedHighNot reported in the sources readOralProhibited (S0 catch-all)
Survodutide Full entryPeptideMetabolicIn Clinical TrialsHighLong enough for weekly dosing; not reported in the abstracts we holdInjectionProhibited (S0 catch-all)
Syn-AkePeptidomimeticCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
TabimorelinSmall molecule, not a peptidePipeline & In-DevelopmentDiscontinuedLowNot reported in the sources readOralProhibited at all times (S2.2.4)
Tachyplesin Full entryPeptideImmuneResearch ChemicalLowNot established for humans; a disulfide-stabilised peptide is more protease-resistant than linear AMPsNot statedNot on the 2026 List
Taldefgrobep alfaProtein, not a peptidePipeline & In-DevelopmentIn Clinical TrialsMediumNot statedInjectionProhibited at all times (S4.3)
Taltirelin Full entryPeptidomimeticCognitiveNot FDA ApprovedMediumNot statedOralUnsettled (S0 may apply)
Taspoglutide Full entryPeptidePipeline & In-DevelopmentDiscontinuedHighNot reported in people in the sources readInjectionProhibited (S0 catch-all)
TB-500 Full entryPeptideHealing & RecoveryResearch ChemicalLowUndetermined in humansInjectionProhibited at all times (S2.3)
TCAP-1 (Teneurin C-terminal Associated Peptide-1) Full entryPeptideCognitiveResearch ChemicalLowNot established for humans as a drug; a teneurin-derived peptideNot statedNot on the 2026 List
Tecemotide Full entryPeptideResearchIn Clinical TrialsMediumNot statedNot statedProhibited (S0 catch-all)
Technetium Tc 99m Apcitide Full entryPeptideResearchDiscontinuedMedium≈ 2 hoursInjectionNot on the 2026 List
Technetium Tc 99m Etarfolatide Full entryNot a peptideResearchDiscontinuedMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Technetium Tc 99m mertiatide Full entryPeptide conjugateResearchFDA ApprovedHighNo elimination half-life stated on the label: nearly 90% of the dose is in urine within 3 hours in healthy subjects (plasma clearance about 0.3 L/min); technetium-99m decays with a 6.02-hour physical half-lifeInjectionNot on the 2026 List
Teduglutide Full entryPeptideMetabolicFDA ApprovedHigh≈ 1.3 hoursInjectionNot on the 2026 List
Teicoplanin Full entryPeptideImmuneNot FDA ApprovedHighNot statedNot statedNot on the 2026 List
TeixobactinPeptideImmunePreclinicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Telavancin Full entryPeptideImmuneFDA ApprovedHigh≈ 8 hoursNot statedNot on the 2026 List
Temporin Full entryPeptideImmuneResearch ChemicalLowNot established for humans; short cationic/hydrophobic peptides subject to proteolysisNot statedNot on the 2026 List
Teprotide Full entryPeptideCardiovascularResearch ChemicalLowNot stated in the sources readInjectionProhibited (S0 catch-all)
Teriparatide Full entryPeptideHealing & RecoveryFDA ApprovedHigh≈ 1 hourInjectionNot on the 2026 List
Terlipressin Full entryPeptideCardiovascularFDA ApprovedHigh≈ 0.9 hoursInjectionUnsettled (S5 may apply)
Tertomotide Full entryPeptideResearchNot FDA ApprovedHighNot reported in the sources readInjectionUnsettled (S0 may apply)
Tesamorelin Full entryPeptideGrowth HormoneFDA ApprovedHigh8–11 minutes (current labels)InjectionProhibited at all times (S2.2.4)
Tesofensine Full entrySmall molecule, not a peptideResearchIn Clinical TrialsMedium≈ 234 hoursOralProhibited in competition (S6.B)
TestagenPeptideLongevityNot FDA ApprovedLowNot reported in the sources readOralProhibited (S0 catch-all)
Tetracosactide Full entryPeptideGrowth HormoneFDA ApprovedHighNot statedInjectionProhibited at all times (S2.2.2)
Tetrapeptide-1PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Tetrapeptide-21PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Tetrapeptide-26PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Tetrapeptide-30PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Teverelix Full entryPeptideSexual HealthIn Clinical TrialsMedium24-75 hours after single 0.5-5 mg doses; depot release from large dosesInjectionProhibited (S0 catch-all)
Thionin Full entryPeptideImmuneResearch ChemicalLowNot established for humans; disulfide-stabilised and relatively stableNot statedNot on the 2026 List
Thiostrepton Full entryPeptideImmuneResearch ChemicalLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Thrombomodulin Alfa Full entryProtein, not a peptideCardiovascularNot FDA ApprovedHigh≈ 20 hoursInjectionUnsettled (S0 may apply)
Thymalin Full entryBlend or mixtureLongevityNot FDA ApprovedLowNot establishedInjectionUnsettled (S0 may apply)
ThymoctonanPeptideImmuneDiscontinuedLowUnder 6 minutes in human whole blood at 37 °C (2020)InjectionProhibited (S0 catch-all)
Thymodepressin Full entryPeptideImmuneNot FDA ApprovedLowNot reported in the sources readInjectionUnsettled (S0 may apply)
Thymogen Full entryPeptideLongevityNot FDA ApprovedLowNot reported in the abstracts readInjection, NasalUnsettled (S0 may apply)
Thymomodulin Full entryBlend or mixtureImmuneNot FDA ApprovedMediumNot reported in the sources readOralProhibited (S0 catch-all)
Thymopentin Full entryPeptideImmuneNot FDA ApprovedMediumExtremely short in the body; not measured in people in the sources readInjectionProhibited (S0 catch-all)
Thymosin α1 Full entryPeptideImmuneNot FDA ApprovedHigh≈ 2 hoursInjectionUnsettled (S0 may apply)
Thymosin β4 Full entryPeptideHealing & RecoveryIn Clinical TrialsMediumNot reported in the abstracts we holdTopical or eyeProhibited at all times (S2.3)
Thymostimulin Full entryBlend or mixtureImmuneNot FDA ApprovedMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Thymulin Full entryPeptideImmuneResearch ChemicalLowAbout 10 minutes in sheep; not measured in peopleInjectionProhibited (S0 catch-all)
Thyrotropin alfa Full entryProtein, not a peptideGrowth HormoneFDA ApprovedHigh≈ 25 hoursInjectionNot on the 2026 List
Tifuvirtide Full entryPeptideImmuneDiscontinuedMediumNot statedInjectionProhibited (S0 catch-all)
TiplimotidePeptideImmuneNot FDA ApprovedMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Tirzepatide Full entryPeptideMetabolicFDA ApprovedHigh≈ 5 daysInjectionNot on the 2026 List
TLQP-21 Full entryPeptideMetabolicResearch ChemicalLowNot established for humans as a drug; an endogenous VGF-derived peptideNot statedNot on the 2026 List
Tozuleristide Full entryPeptide conjugateResearchIn Clinical TrialsMedium≈ 30 minutesInjectionProhibited (S0 catch-all)
Trafermin Full entryProtein, not a peptideHealing & RecoveryNot FDA ApprovedHighNot stated as a figure in the sources readTopical or eyeProhibited at all times (S2.3)
TrevogrumabAntibody, not a peptidePipeline & In-DevelopmentIn Clinical TrialsLowNot reported in the sources readInjectionProhibited at all times (S4.3)
Trifluoroacetyl Tripeptide-2PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Tripeptide-10 CitrullinePeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Tripeptide-29PeptideCosmeticResearch ChemicalLowNot reported in the sources readOral, Topical or eyeUnsettled (S0 may apply)
Tripeptide-32PeptideCosmeticResearch ChemicalLowNot reported in the sources readTopical or eyeUnsettled (S0 may apply)
Triptorelin Full entryPeptideSexual HealthFDA ApprovedHighNot reported in the sources readInjectionProhibited in males, at all times (S2.2.1)
Trivehexin Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Trofinetide Full entryPeptideCognitiveFDA ApprovedHigh≈ 1.5 hoursOralNot on the 2026 List
Trofolastat Full entrySmall molecule, not a peptideResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Tuftsin Full entryPeptideImmuneResearch ChemicalMediumNot reported in the sources readNot statedProhibited (S0 catch-all)
Tyrothricin Full entryBlend or mixtureImmuneNot FDA ApprovedMediumNot reported in the sources readTopical or eyeNot on the 2026 List
Ubiquicidin 29-41 Full entryPeptideResearchIn Clinical TrialsMediumBlood mean residence time 0.52 hours in 6 children; about 85% of the activity left in the urine within 24 hoursInjectionProhibited (S0 catch-all)
UBT251PeptidePipeline & In-DevelopmentIn Clinical TrialsMediumSupports once-weekly dosingInjectionProhibited (S0 catch-all)
Ularitide Full entryPeptideCardiovascularDiscontinuedHigh≈ 5.6 minutesInjectionProhibited (S0 catch-all)
Ulimorelin Full entryPeptidomimeticMetabolicIn Clinical TrialsMediumNot statedNot statedProhibited (S0 catch-all)
Urocortin Full entryPeptideCardiovascularResearch ChemicalMedium≈ 52 minutesInjectionProhibited (S0 catch-all)
Urocortin 2 Full entryPeptideCardiovascularResearch ChemicalLowNot stated in the sources readInjectionProhibited (S0 catch-all)
Urocortin 3 Full entryPeptideMetabolicResearch ChemicalLowNot established for humans; an endogenous locally acting neuropeptideNot statedNot on the 2026 List
Urofollitropin Full entryProtein, not a peptideSexual HealthFDA ApprovedHighNot reported in the sources readNot statedNot on the 2026 List
Uroguanylin Full entryPeptideMetabolicResearch ChemicalMediumNot stated in the sources readNot statedProhibited (S0 catch-all)
Urotensin II Full entryPeptideCardiovascularResearch ChemicalLowNot characterised in peopleInjectionProhibited (S0 catch-all)
Urotensin II-related peptide Full entryPeptideCardiovascularResearch ChemicalLowNot stated in the sources readNot statedNot on the 2026 List
UtreglutidePeptidePipeline & In-DevelopmentIn Clinical TrialsLowNot publishedInjectionProhibited (S0 catch-all)
Vancomycin Full entryPeptideImmuneFDA ApprovedHigh≈ 5 hoursInjection, OralNot on the 2026 List
Vapreotide Full entryPeptideMetabolicIn Clinical TrialsHighNot statedNot statedProhibited (S0 catch-all)
Vasopressin Full entryPeptideCardiovascularFDA ApprovedHigh≈ 10 minutesInjectionUnsettled (S5 may apply)
Vasostatin (Chromogranin A) Full entryPeptideCardiovascularResearch ChemicalLowNot established for humans as a drug; an endogenous signalling peptideNot statedNot on the 2026 List
VeldoreotidePeptidePipeline & In-DevelopmentNot FDA ApprovedLowNot reported in the sources readNot statedProhibited (S0 catch-all)
VentfortPeptideLongevityNot FDA ApprovedLowNot reported in the sources readOralProhibited (S0 catch-all)
Vessel dilator Full entryPeptideCardiovascularResearch ChemicalMedium≈ 107 minutesInjectionProhibited (S0 catch-all)
VesugenPeptideLongevityResearch ChemicalLowNot measured in the sources readNot statedProhibited (S0 catch-all)
Vilon Full entryPeptideLongevityResearch ChemicalLowNot statedNot statedProhibited (S0 catch-all)
VIP Full entryPeptideImmuneIn Clinical TrialsMediumMinutes (cleared rapidly from plasma)InjectionUnsettled (S0 may apply)
Vipivotide Tetraxetan Full entryPeptidomimeticResearchFDA ApprovedHigh≈ 41.6 hoursInjectionNot on the 2026 List
Virginiamycin Full entryNot a peptideImmuneVeterinary OnlyLowNot reported in the sources readOralProhibited (S0 catch-all)
VisolutenPeptideLongevityNot FDA ApprovedLowNot reported in the sources readOralProhibited (S0 catch-all)
VK2735PeptidePipeline & In-DevelopmentIn Clinical TrialsMediumLong-acting; given once weekly by injectionInjectionProhibited (S0 catch-all)
VMT-α-NET Full entryPeptide conjugateResearchIn Clinical TrialsMediumNot reported in the sources readInjectionProhibited (S0 catch-all)
Voclosporin Full entryPeptideImmuneFDA ApprovedHigh≈ 30 hoursOralNot on the 2026 List
Vosoritide Full entryPeptideGrowth HormoneFDA ApprovedHigh≈ 25 minutesInjectionNot on the 2026 List
WE-14 Full entryPeptideMetabolicResearch ChemicalLowNot established for humans as a drug; an endogenous granin peptideNot statedNot on the 2026 List
Xenin Full entryPeptideMetabolicResearch ChemicalMediumNot stated in the sources readInjectionProhibited (S0 catch-all)
Zadavotide Guraxetan Full entryPeptidomimeticResearchIn Clinical TrialsMedium≈ 35 hoursInjectionProhibited (S0 catch-all)
Zelenectide Pevedotin Full entryPeptide conjugateResearchIn Clinical TrialsMedium1-2 hours in rats and monkeys; no human figure in the abstracts readInjectionProhibited (S0 catch-all)
Zelpultide alfaProtein, not a peptidePipeline & In-DevelopmentIn Clinical TrialsLowNot reported in the sources readNot statedProhibited (S0 catch-all)
Ziconotide Full entryPeptideCognitiveFDA ApprovedHigh≈ 4.6 hoursNot statedNot on the 2026 List
Zilucoplan Full entryPeptideImmuneFDA ApprovedHigh≈ 172 hoursInjectionNot on the 2026 List
Zoptarelin Doxorubicin Full entryPeptide conjugateResearchDiscontinuedMediumNot statedNot statedProhibited (S0 catch-all)
αCT1 (Alpha Connexin Carboxyl-Terminus 1) Full entryPeptideHealing & RecoveryIn Clinical TrialsMediumShort; rapid metabolism of the free peptide is reported, motivating sustained-release and gel formulationsTopical or eyeNot on the 2026 List

How to read the columns

  • Class says whether an entry is a peptide at all. Proteins, antibodies, small molecules and blends are marked as not peptides, from each entry's own description.
  • FDA status is the US position only. "Not FDA Approved" can still mean approved elsewhere; the entry says where.
  • Evidence is our grade of the human evidence: high for controlled human trials large enough to answer the question, typically a completed phase 3 programme or a reviewed approval dossier; medium for published human results short of that; low for cell or animal work, case reports, or nothing.
  • Half-life shows a measured or labelled value when the entry has one; hover or tap for the source note. "Not measured" is a finding, not a gap in the table.
  • Route is how the entry's studies or label give it, not a suggestion. An entry can have more than one.
  • WADA 2026 is the sport status in the List in force. "Prohibited (S0 catch-all)" means, on our reading, an unapproved substance caught by WADA's catch-all section without being named; a substance the List names, such as BPC-157 under S0, shows as prohibited.

The dataset behind this table is updated as entries are rewritten; each entry page carries its last-reviewed date.